Fortis Healthcare Reports Strong Q2 FY26 Results, Operational Growth, and Releases Investors' Meet Transcript
Fortis Healthcare reported strong Q2 FY26 results with consolidated revenue up 17.3% to ₹2,331 crores and EBITDA up 28% to ₹556 crores. Hospital and diagnostics segments showed robust growth and margin expansion, alongside strategic bed additions and acquisitions.
The announcement details significant financial performance, including strong revenue and EBITDA growth, and improved profitability. It also outlines key strategic initiatives such as bed expansions, new O&M agreements, and acquisitions, which are expected to drive future growth. These factors collectively indicate a high impact on the company's operational and financial trajectory.
The company reported strong double-digit growth in both consolidated revenue and operating EBITDA, along with significant margin expansion in both hospital and diagnostics segments. Strategic expansions through new leases, O&M agreements, and acquisitions, coupled with a positive outlook for continued growth and margin improvement, contribute to a positive sentiment.
Fortis Healthcare Limited has released the transcript of its Investors/Analysts' meet held on November 12, 2025, which discussed the company's unaudited financial results for the quarter and half year ended September 30, 2025. * Consolidated Financial Highlights (Q2 FY26): * Revenue grew 17.3% year-on-year (YoY) to ₹2,331 crores. * Operating EBITDA increased 28% YoY to ₹556 crores, with a margin of 23.9% (up from 21.9% in Q2 FY25). * Profit After Tax (PAT) before exceptional items rose 20.7% to ₹305 crores. * Hospital Business (Q2 FY26): * Revenue grew 19.3% to ₹1,974 crores. * Operating EBITDA was ₹452 crores, with a margin of 22.9% (up from 21.4% in Q2 FY25). * Occupancy improved to 71% (from 69% in Q1 FY26), with occupied beds increasing 13% to 3,318. * Average Revenue Per Occupied Bed (ARPOB) increased 5.8% to ₹2.51 crores per annum, driven by an improved specialty mix, particularly oncology (up 29% YoY). * Medical travel revenue grew 26% to ₹169 crores, contributing 8.1% to hospital revenue. * Strategic expansions include a 15-year lease agreement for a 200-bedded multi-specialty hospital in Greater Noida and an O&M agreement for a 550-bedded greenfield hospital in Lucknow. * The company also consummated the acquisition of Shrimann Super Speciality Hospital in Jalandhar and entered an O&M agreement with Gleneagles India for five hospitals and a clinic (excluding Mumbai). * 550 operational beds were added in H1 FY26 through brownfield expansion, Jalandhar acquisition, and the Greater Noida arrangement. * Diagnostics Business (Agilus) (Q2 FY26): * Gross revenue grew 7.3% to ₹400 crores. * Operating EBITDA margin stood at 26.1% (up from 21.5% in Q2 FY25). * 10.6 million tests were conducted, and 7 new labs and 200+ customer touchpoints were added. * The genomics portfolio grew by 20%, and 19 new tests were launched. * Half Year (H1 FY26) Consolidated: * Revenues stood at ₹4,498 crores, up 16.9% YoY. * Operating EBITDA increased to ₹1,047 crores, with a margin of 23.3% (up from 20.2% in H1 FY25). * Balance Sheet: Net debt was ₹2,219 crores, with a net debt-to-EBITDA of 0.96x as of September 30, 2025, primarily due to recent acquisitions. * Outlook: Management expects positive growth momentum to continue, with diagnostics margins around 23-24% for the full year. Hospital top-line growth is expected to sustain in H2, with potential for higher margin improvement than initially guided. The FMRI capacity addition is now expected by March end 2026. The company remains keen on evaluating further growth opportunities.
What to do with a filing like this
Fortis Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fortis Healthcare Limited. Read the original for the full detail.